CNS Trial Failure Rates High As Need For New Drugs Grows

We need to improve the conduct of CNS trials. The failure rate of CNS drugs in phase 2 and 3 clinical trials is around 85%, second only to Oncology. Because of this failure rate, many large pharmaceutical companies are exiting the space. At the same time, the need for CNS therapies has never been more acute, and there is a pressing need for both disease modifying and symptomatic treatments.